Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.19.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2019
Share-based Payment Arrangement [Abstract]  
Summary of employee and nonemployee stock option activity
A summary of employee and non-employee stock option activity for the six months ended June 30, 2019 is as follows:
 
Options Outstanding
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in thousands)
 
Number of
Shares
(in thousands)
 
Weighted-
Average
Exercise
Price
 
Outstanding January 1, 2019
3,004

 
$
5.77

 
5.70
 
$
—

Granted
95

 
0.44

 
 
 
 
Cancelled or expired
(1,356
)
 
5.55

 
 
 
 
Outstanding June 30, 2019
1,743

 
$
5.66

 
6.91
 
$
—

Exercisable June 30, 2019
1,149

 
$
7.92

 
5.93
 
$
—

Weighted-average assumptions used to estimate fair value of options granted
The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2019
 
2018
Volatility
77.81
%
 
90.15
%
 
77.81
%
Risk free interest rate
2.89
%
 
2.54
%
 
2.89
%
Dividend yield
0.00
%
 
0.00
%
 
0.00
%
Term (years)
6.49

 
6.32

 
6.49

Weighted-average fair value of options granted during the period
$
0.63

 
$
0.34

 
$
0.63

Nonvested restricted stock shares activity
The following table summarizes the activities for our non-vested restricted stock awards for the six months ended June 30, 2019:
 
Non-vested Restricted Stock Awards
 
Number of
Shares
(in thousands)
 
Weighted-Average Grant Date Fair Value
Non-vested at January 1, 2019
29

 
$
3.43

Vested
(9
)
 
4.15

Cancelled
(1
)
 
6.30

Non-vested at June 30, 2019
19

 
$
2.94

Summary of the effects of stock-based compensation related to stock option and restricted stock awards
The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss during the periods presented (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Cost of revenues
$
28

 
$
90

 
$
56

 
$
181

Research and development
7

 
16

 
15

 
31

General and administrative
62

 
140

 
178

 
298

Sales and marketing
5

 
22

 
11

 
32

Total stock-based compensation
$
102

 
$
268

 
$
260

 
$
542